DS in Pharmatics

JANUARY 11, 2025

Regulatory compliance defines success in biopharmaceuticals and medical devices. A missed step can lead to recalls, financial losses, or patient harm. Quality assurance (QA) consultants, like DSI, help companies tackle these risks. Our expertise strengthens compliance strategies, mitigates issues, and boosts operational efficiency.

Compliance 52

Compliance 52

Covalent Modifiers

JANUARY 11, 2025

Bryn Marie Reimer, Ernest Awoonor-Williams, Andrei A. Golosov, and Viktor Hornak Journal of Chemical Information and Modeling 2025 DOI: 10.1021/acs.jcim.4c01281 Targeted covalent inhibition is a powerful therapeutic modality in the drug discoverers toolbox. Recent advances in covalent drug discovery, in particular, targeting cysteines, have led to significant breakthroughs for traditionally challenging targets such as mutant KRAS, which is implicated in diverse human cancers.

Drugs 162

Drugs 162

Covalent Modifiers

JANUARY 11, 2025

Fangyuan Chen, Qingmei Liu, Lei Ma, Cuishi Yan, Haiman Zhang, Zhi Zhou, and Wei Yi Journal of Medicinal Chemistry 2025 68 (1), 819-831 DOI: 10.1021/acs.jmedchem.4c02803 Recent studies have identified selective peroxisome proliferator-activated receptor (PPAR) modulators, which synergistically engage in the inhibition mechanism of PPAR-Ser273 phosphorylation, as a promising approach for developing safer and more effective antidiabetic drugs.

Drugs 147

Drugs 147